Holmium Laser Xpeeda Vaporesection Versus Greenlight XPS Vaporization of the Prostate for Benign Prostatic Obstruction: A Randomized Controlled Clinical Study
The clinical trial compares two advanced laser technologies for treating benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS). The Holmium Xpeeda fiber is positioned as a potentially superior alternative to the Greenlight XPS system, emphasizing efficiency and reduced operative time. The successful demonstration of improved outcomes could enhance market adoption of the Xpeeda technology, particularly in the minimally invasive surgery segment. Given the prevalence of BPH, which affects a significant portion of the male population over 50, the market potential is substantial. The results may influence purchasing decisions in urology departments and impact competitive dynamics among laser device manufacturers.
Indication: Benign Prostatic Hyperplasia
Modality: combination therapy
Target: Holmium laser technology for prostate vaporesection and vaporization procedures.
Sponsor: Thunder Bay Regional Health Research Institute
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Holmium laser technology for prostate vaporesection and vaporization procedures.
View original source fields
Condition raw: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Condition normalized: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: Holmium laser technology for prostate vaporesection and vaporization procedures.
Target normalized: Holmium laser technology for prostate vaporesection and vaporization procedures.